


SCD1-IN-1

Cat. No.:	HY-150125
CAS No.:	1111078-63-7
Molecular Formula:	C ₂₀ H ₂₀ F ₃ NO ₄
Molecular Weight:	395.37
Target:	Stearoyl-CoA Desaturase (SCD)
Pathway:	Metabolic Enzyme/Protease
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	SCD1-IN-1 is a SCD1 inhibitor (IC ₅₀ : 5.8 nM). SCD1-IN-1 can be used in the research of dermatologic condition ^[1] .								
IC₅₀ & Target	SCD1 ^[1] .								
In Vitro	SCD1-IN-1 (compound I, 6 days) inhibits the SCD1 enzyme in intact human cells, with an IC ₅₀ value of 6.8 nM ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.								
In Vivo	<p>SCD1-IN-1 (compound I, 1.5% w/v, 25 μL, applied to surfaces of ears) reduces in cholesterol ester (CE) and wax ester (WE) production in hamster ear model^[1].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1"> <tr> <td>Animal Model:</td> <td>Hamster ear model^[1]</td> </tr> <tr> <td>Dosage:</td> <td>1.5% in a vehicle of propylene glycol/transcutanol/ethanol 20/20/60, w/v, 25 μL.</td> </tr> <tr> <td>Administration:</td> <td>Applied to ~3 cm² of the ventral surfaces of both the right and left ears, twice daily for 2 weeks.</td> </tr> <tr> <td>Result:</td> <td>Resulted in a 62% reduction in CE and an 82% reduction in WE, a mechanism biomarker for sebum production in the hamster model, and a reduction in sebaceous gland size.</td> </tr> </table>	Animal Model:	Hamster ear model ^[1]	Dosage:	1.5% in a vehicle of propylene glycol/transcutanol/ethanol 20/20/60, w/v, 25 μL.	Administration:	Applied to ~3 cm ² of the ventral surfaces of both the right and left ears, twice daily for 2 weeks.	Result:	Resulted in a 62% reduction in CE and an 82% reduction in WE, a mechanism biomarker for sebum production in the hamster model, and a reduction in sebaceous gland size.
Animal Model:	Hamster ear model ^[1]								
Dosage:	1.5% in a vehicle of propylene glycol/transcutanol/ethanol 20/20/60, w/v, 25 μL.								
Administration:	Applied to ~3 cm ² of the ventral surfaces of both the right and left ears, twice daily for 2 weeks.								
Result:	Resulted in a 62% reduction in CE and an 82% reduction in WE, a mechanism biomarker for sebum production in the hamster model, and a reduction in sebaceous gland size.								

REFERENCES

[1]. Li Jin, et al. Phenoxy-pyrrolidine derivative and its use and compositions Patent. WO2009019566.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA